U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07822880) titled 'A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India' on Sept. 11.
Brief Summary: This study will evaluate the safety of selpercatinib in participants with RET-altered cancers in India. The study will also assess the number of changes and why participants stop study treatment.
For each participant, the study is expected to last 56 weeks and will include up to 16 protocol-specific visits.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Thyroid Neoplasms
Carcinoma, Non-Small-Cell Lung
Intervention:
DRUG: Selpercatinib
Tablet administered ora...